<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25891" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nimodipine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Das</surname>
            <given-names>Joe M.</given-names>
          </name>
          <aff>Imperial College Healthcare NHS Trust, London</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Joe Das declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25891.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nimodipine is a second-generation 1,4-dihydropyridine calcium channel blocker that&#x000a0;was originally approved by the FDA to manage hypertension. Today, nimodipine is predominantly used to manage vasospasm subsequent to subarachnoid hemorrhage, in addition to off-label applications.&#x000a0;Nimodipine is available&#x000a0;in various formulations, including oral tablets, solutions, and intravenous infusions. This discussion will primarily focus on&#x000a0;this medication's administration methods and associated considerations. Equally important are the indications, mechanisms of action, adverse effects, contraindications, and monitoring associated with nimodipine administration. Healthcare professionals must have a deep comprehension of this medication in order to use it effectively. This&#x000a0;informed decision-making not only optimizes dosage regimens but also mitigates adverse reactions, facilitating enhanced patient outcomes in subarachnoid hemorrhage scenarios treated with nimodipine.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of nimodipine.</p></list-item><list-item><p>Differentiate between&#x000a0;the FDA-approved indications and the off-label indications of&#x000a0;nimodipine.</p></list-item><list-item><p>Identify&#x000a0;the contraindications of nimodipine.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from&#x000a0;nimodipine&#x000a0;treatment.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25891&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25891">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25891.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nimodipine (C<sub>21</sub>H<sub>26</sub>N<sub>2</sub>O<sub>7</sub>) is a second-generation 1,4-dihydropyridine calcium channel blocker initially developed to manage systemic hypertension. The FDA approved its use&#x000a0;in 1988. However, its current use is restricted&#x000a0;primarily&#x000a0;to managing vasospasm following subarachnoid hemorrhage.</p>
        <p>
<bold>FDA-Approved Indication</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Prevention and treatment of cerebral vasospasm following subarachnoid hemorrhage. Nimodipine is indicated to improve neurological outcomes by reducing the incidence and severity of ischemic deficits regardless of their post-ictus neurological condition.<xref ref-type="bibr" rid="article-25891.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Off-Label Uses</bold></p>
        <list list-type="bullet">
          <list-item>
            <p>Diffuse brain injury along with hyperbaric oxygen therapy <xref ref-type="bibr" rid="article-25891.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Assisting recovery after cranial nerve injury&#x000a0;<xref ref-type="bibr" rid="article-25891.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Migraine&#x000a0;prevention&#x000a0;<xref ref-type="bibr" rid="article-25891.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Peripheral vertigo and M&#x000e9;ni&#x000e8;re disease&#x000a0;<xref ref-type="bibr" rid="article-25891.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Reducing the development of postoperative delirium in&#x000a0;older patients under general anesthesia&#x000a0;<xref ref-type="bibr" rid="article-25891.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Drug-resistant epilepsy&#x000a0;<xref ref-type="bibr" rid="article-25891.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Orgasmic and bath-related headaches&#x000a0;<xref ref-type="bibr" rid="article-25891.r8">[8]</xref><xref ref-type="bibr" rid="article-25891.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Potential for glaucoma&#x000a0;management as an ophthalmic formulation&#x000a0;<xref ref-type="bibr" rid="article-25891.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>The following findings are derived from various trials regarding the use of nimodipine:</p>
        <list list-type="bullet">
          <list-item>
            <p>One recent study&#x000a0;reports that a considerable risk of mortality and morbidity is associated with SAH; nearly half of survivors experience significant cognitive dysfunction that affects their functional status and quality of life. Besides the severity of the initial hemorrhage, secondary brain injury resulting from early brain injury and delayed cerebral ischemia significantly impacts&#x000a0;outcomes for&#x000a0;patients with SAH. Although numerous strategies to address secondary brain injury have been explored, only nimodipine has demonstrated effectiveness in improving long-term functional outcomes.<xref ref-type="bibr" rid="article-25891.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Current evidence suggests nimodipine may reduce the risk of death or vegetative state related to delayed cerebral ischemia (DCI). However, some studies also indicate that fixed-dose regimens may decrease mortality and infarction rates. Further research is needed to determine nimodipine's broader benefits and the optimal dosing strategy&#x000a0;for contemporary practice.<xref ref-type="bibr" rid="article-25891.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Reducing&#x000a0;nimodipine doses must be performed cautiously in patients with high vasopressor demand after an aneurysmal subarachnoid hemorrhage (aSAH). One study examined risks during days 5 to 10 post-hemorrhage. Among 205 patients, 53% had reduced dosage ('reduction group'). This group had worse World Federation of Neurosurgical Societies (WFNS) and Fisher grades and more delayed cerebral ischemia (DCI), cerebral vasospasm (CVS), DCI-related infarction, and other unfavorable outcomes. Multivariable analysis identified 'reduced nimodipine dose' as the sole predictor for DCI and CVS. 'Poor WFNS grade' and 'reduced nimodipine dose' were linked to DCI-related infarction, while 'older age,' 'poor WFNS grade,' and 'reduced nimodipine dose' correlated with unfavorable outcomes at&#x000a0;3&#x000a0;months. This study concludes that reducing nimodipine dosage during days 5 to 10 post-hemorrhage might negate its benefits and should be carefully considered.<xref ref-type="bibr" rid="article-25891.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine should be given to patients with no neurological deficits after subarachnoid hemorrhage to reduce the&#x000a0;risk of new neurological deficits due to vasospasm.<xref ref-type="bibr" rid="article-25891.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Oral nimodipine 60 mg every 4 hours was well tolerated, reduced cerebral infarction, and improved outcomes after a subarachnoid hemorrhage.<xref ref-type="bibr" rid="article-25891.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>There is no statistically proven benefit of nimodipine in head injury patients.<xref ref-type="bibr" rid="article-25891.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine has no role in improving the functional outcome of acute ischemic hemispheric stroke.<xref ref-type="bibr" rid="article-25891.r16">[16]</xref></p>
          </list-item>
          <list-item>
            <p>There is no benefit of nimodipine in the treatment of head injury patients.<xref ref-type="bibr" rid="article-25891.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine has a minimal role in the&#x000a0;prevention of migraine without aura.<xref ref-type="bibr" rid="article-25891.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <p>Researchers noted a beneficial effect&#x000a0;of nimodipine in acute cerebral ischemia.<xref ref-type="bibr" rid="article-25891.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine may be effective in patients with small vessel subcortical vascular dementia.<xref ref-type="bibr" rid="article-25891.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Early supplementation of nimodipine in stroke patients does&#x000a0;not have any beneficial effect.<xref ref-type="bibr" rid="article-25891.r21">[21]</xref></p>
          </list-item>
          <list-item>
            <p>Oral and intravenous nimodipine are equally efficient in preventing vasospasm following subarachnoid hemorrhage.<xref ref-type="bibr" rid="article-25891.r22">[22]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine has a potential neuroprotective effect by preventing calcium overload in ischemic neurons. However, this is outweighed by its harmful hemodynamic effects in the ischemic area in treating acute ischemic stroke.</p>
          </list-item>
          <list-item>
            <p>One Phase&#x000a0;III randomized trial compared the efficacy and safety&#x000a0;of&#x000a0;single intraventricular administration&#x000a0;nimodipine microparticles to the standard oral nimodipine&#x000a0;in patients with SAH.&#x000a0;The trial concluded that sustained release nimodipine administered via external ventricular drain did not&#x000a0;significantly increase favorable outcomes compared with the standard of care.<xref ref-type="bibr" rid="article-25891.r23">[23]</xref><xref ref-type="bibr" rid="article-25891.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>A recent&#x000a0;innovative&#x000a0;formulation has connected nimodipine with pH-sensitive chitosan nanoparticles. The objective of using&#x000a0;this technique&#x000a0;is to maintain systemic administration of nimodipine but restrict the release of the drug to tissues&#x000a0;in the ischemic penumbra with a lower pH.<xref ref-type="bibr" rid="article-25891.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25891.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>During the depolarization of smooth muscle cells of blood vessels, there is an influx of calcium ions. The primary function of nimodipine is to block voltage-gated L-type calcium channels and keep them in their inactive conformation, preventing vasoconstriction. Nimodipine&#x000a0;preferentially acts on cerebral blood vessels because it is lipophilic and can cross the blood-brain barrier.<xref ref-type="bibr" rid="article-25891.r26">[26]</xref>&#x000a0;Proposed mechanisms&#x000a0;leading to a beneficial effect include decreased angiographic vasospasm, increased fibrinolytic activity, and enhanced neuroprotection.<xref ref-type="bibr" rid="article-25891.r25">[25]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Nimodipine is rapidly absorbed after oral administration, and peak concentration is achieved within 1.5 hours. Due to an elevated first-pass metabolism, the bioavailability of nimodipine is approximately 13% after oral administration.&#x000a0;Taking nimodipine with&#x000a0;meals results in a decreased peak plasma concentration and lower bioavailability&#x000a0;compared to fasting.</p>
        <p><bold>Distribution:</bold> The volume&#x000a0;of distribution (Vd) of nimodipine varies from 0.94&#x000a0;L/kg to 2.46&#x000a0;L/kg.&#x000a0;Nimodipine is&#x000a0;approximately 95% bound to plasma proteins, primarily to &#x003b1;-acid glycoprotein. Accordingly, the concentration of &#x003b1;-acid glycoprotein can influence the distribution of nimodipine.</p>
        <p><bold>Metabolism:</bold> Nimodipine is metabolized by&#x000a0;CYP3A4 and CYP3A5. Multiple inactive or less active metabolites have been identified.</p>
        <p><bold>Elimination:</bold> The terminal elimination half-life of nimodipine is approximately 8 to 9 hours, but initial elimination is rapid (equivalent to a half-life of 1 to 2 hours); frequent (every 4 hours) dosing is necessary. Nimodipine is excreted primarily via the kidney, and less than 1% of the parent drug is recovered unchanged in the urine. Pharmacokinetic studies have documented the variability of nimodipine concentrations in patients with subarachnoid hemorrhage.<xref ref-type="bibr" rid="article-25891.r27">[27]</xref></p>
      </sec>
      <sec id="article-25891.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms</bold>
</p>
        <p>Nimodipine is available as oral tablets, oral solutions, and intravenous infusion solutions. However, the FDA has not approved the intravenous infusion solution, and this formulation is unavailable in the U.S.&#x000a0;</p>
        <p>Nimodipine is available as a 30 mg oral capsule and an oral solution (6 mg/mL).</p>
        <p>The Neurocritical Care Society guidelines suggest that all patients with aneurysmal subarachnoid hemorrhage should receive oral nimodipine 60 mg every&#x000a0;4 hours for 21 days&#x000a0;after an SAH occurs.<xref ref-type="bibr" rid="article-25891.r28">[28]</xref>&#x000a0;</p>
        <p>
<bold>Oral Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nimodipine is available as liquid-filled oral capsules (30 mg) and oral solution (6 mg/mL and 30 mg/10 mL strength [unit-dose prefilled syringe and 8 oz container]). This drug must be administered at least 1 hour before or 2 hours after meals.</p>
          </list-item>
          <list-item>
            <p>Nimodipine should be administered&#x000a0;as early as possible but must&#x000a0;be administered within 96 hours of&#x000a0;a diagnosis of subarachnoid hemorrhage.&#x000a0;The recommended dose for adults is 60 mg (as 2 30 mg capsules) every 4 hours for 21 consecutive days.</p>
          </list-item>
          <list-item>
            <p>If the patient is not conscious enough to swallow the nimodipine capsule, the contents&#x000a0;can be&#x000a0;extracted into a syringe,&#x000a0;fed through a nasogastric tube, and washed down with 30 mL of normal saline (0.9%).</p>
          </list-item>
        </list>
        <p>
<bold>Intravenous Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Parental administration is strongly discouraged (see USFDA&#x000a0;boxed warning). The following parenteral techniques are described for educational purposes only. Nimodipine&#x000a0;can be given intravenously via a central venous catheter at a starting dose of 1 mg/h (15 &#x003bc;g/kg/h, equivalent to 5 mL/h) for the first 2 hours.&#x000a0;If the patient tolerates the drug well&#x000a0;without hypotension, the dose can&#x000a0;increase&#x000a0;to 2 mg/h (30 &#x003bc;g/kg/h, equivalent to 10 mL/h) after the first 2 hours.</p>
          </list-item>
          <list-item>
            <p>If the patient has hypotension or a body weight of less than 70 kg, nimodipine should&#x000a0;be started at 0.5 mg/h (2.5 mL of solution per hour) or less, if necessary.</p>
          </list-item>
        </list>
        <p>
<bold>Intraventricular Administration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The outcome, dosage, and duration of intraventricular&#x000a0;nimodipine administration&#x000a0;were assessed in the NEWTON trial. The results of this trial indicated no significant&#x000a0;benefit for&#x000a0;intraventricular nimodipine compared with the standard of care.<xref ref-type="bibr" rid="article-25891.r23">[23]</xref><xref ref-type="bibr" rid="article-25891.r29">[29]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Aneurysmal Subarachnoid Hemorrhage Treatment&#x000a0;Duration</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous administration should be started as soon as possible after the onset of clinical vasospasm and should continue for a minimum of 5 days and a maximum of 14 days. If the condition&#x000a0;requires surgical intervention, nimodipine should&#x000a0;be administered at a steady&#x000a0;dose for at least 5 days.</p>
          </list-item>
          <list-item>
            <p>Intravenous nimodipine administration can begin&#x000a0;with or without pre-treatment with nimodipine tablets. However, if&#x000a0;nimodipine is administered intravenously following oral administration, the total duration of treatment should not exceed 21 days.</p>
          </list-item>
          <list-item>
            <p>Nimodipine should not be&#x000a0;administered intravenously&#x000a0;for more than 14 days. Patients should not&#x000a0;be administered intravenous and oral nimodipine concomitantly.</p>
          </list-item>
          <list-item>
            <p>During a surgical procedure, a 20 mL diluted solution of nimodipine (1 ml of nimodipine concentrated intravenous infusion solution and 19 mL of Ringer solution) warmed up to blood temperature may be&#x000a0;administered&#x000a0;intracisternally. This diluted solution must be used immediately after preparation.</p>
          </list-item>
        </list>
        <p>
<bold>Specific Patient Population&#x000a0;</bold>
<xref ref-type="bibr" rid="article-25891.r28">[28]</xref>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Bioavailability increases in patients with cirrhosis, making it necessary to reduce the dose in patients with this condition. The recommended dosage for patients with cirrhosis is 30 mg every 4 hours.&#x000a0;</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No information is available&#x000a0;on the manufacturer's label concerning&#x000a0;nimodipine dosing for patients with impaired renal function.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Nimodipine&#x000a0;is a former U.S. FDA pregnancy category C medicine, and alternative agents are preferred.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Based on the available data, nimodipine is&#x000a0;present in human milk; relative infant exposure is less and is not expected to cause adverse effects in breastfed infants. However, the decision to breastfeed during an episode of SAH merits a risk-benefit evaluation.<xref ref-type="bibr" rid="article-25891.r30">[30]</xref></p>
        <p><bold>Pediatric patients:&#x000a0;</bold>Nimodipine&#x000a0;is not FDA-approved for pediatric patients. Research indicates that administering oral nimodipine to children following subarachnoid hemorrhage does not eliminate vasospasm, infarction, or rebleeding. Nimodipine is also associated with significant hypotension. Further investigation, including dose titration, is&#x000a0;necessary&#x000a0;before administration to pediatric patients can be advised.<xref ref-type="bibr" rid="article-25891.r31">[31]</xref></p>
        <p><bold>Older patients:</bold>&#x000a0;In older patients, clinicians should be cautious when dosing nimodipine&#x000a0;for patients with&#x000a0;reduced cardiac, hepatic,&#x000a0;or renal function. One case report&#x000a0;suggests that adverse effects like hypotension and AV block from nimodipine&#x000a0;can be more pronounced in older patients who&#x000a0;have&#x000a0;a&#x000a0;"poor metabolizer" CYP3A5 genotype.<xref ref-type="bibr" rid="article-25891.r32">[32]</xref></p>
      </sec>
      <sec id="article-25891.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Nimodipine is usually well-tolerated orally, but its use correlates with some side effects related to&#x000a0;its use as a vasodilator. The&#x000a0;most common adverse effects of this medication include headache, vertigo, flushing, nausea, diarrhea, pedal edema, rash,&#x000a0;and palpitations.</p>
        <p>Acute colonic pseudo-obstruction (Ogilvie syndrome) has been&#x000a0;documented&#x000a0;in patients administered oral nimodipine.<xref ref-type="bibr" rid="article-25891.r33">[33]</xref>&#x000a0;Internal carotid and middle cerebral artery narrowing&#x000a0;leading to cerebral infarction have been reported&#x000a0;5 months after&#x000a0;intraventricular administration&#x000a0;of sustained-release nimodipine.<xref ref-type="bibr" rid="article-25891.r29">[29]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Nimodipine is&#x000a0;metabolized by the cytochrome P450 3A4 system. Drugs that inhibit this enzyme can&#x000a0;cause&#x000a0;elevated plasma concentrations of nimodipine.&#x000a0;These drugs include macrolide antibiotics (eg, erythromycin, clarithromycin, and telithromycin), protease inhibitors (eg, ritonavir, indinavir, nelfinavir, and saquinavir), "-azole" antimycotics (eg, ketoconazole, voriconazole, itraconazole), antidepressants (eg, nefazodone, fluoxetine), quinupristin/dalfopristin, cimetidine, and valproic acid. Grapefruit juice also inhibits this cytochrome system and should be avoided&#x000a0;by any patient&#x000a0;taking nimodipine.<xref ref-type="bibr" rid="article-25891.r32">[32]</xref></p>
        <p>Medications including&#x000a0;carbamazepine, phenobarbital (phenobarbitone), and phenytoin are CYP3A4 inducers. Concomitant administration of any of these medications enhances nimodipine's metabolism. This process&#x000a0;reduces nimodipine's serum concentration and increases the likelihood of treatment failure.<xref ref-type="bibr" rid="article-25891.r34">[34]</xref></p>
      </sec>
      <sec id="article-25891.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The following are contraindications to nimodipine administration:</p>
        <list list-type="bullet">
          <list-item>
            <p>A history of hypersensitivity reaction to nimodipine is an absolute contraindication.</p>
          </list-item>
          <list-item>
            <p>Liver failure and hypotension are relative contraindications for administering nimodipine.</p>
          </list-item>
          <list-item>
            <p>Concomitant administration with potent CYP3A4 inhibitors is also a relative contraindication.<xref ref-type="bibr" rid="article-25891.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Nimodipine is not entirely safe&#x000a0;for pregnancy (Category C under the former FDA system), and patients who are pregnant should only use it if a strong benefit-risk ratio has been determined. Breastfeeding is contraindicated while taking the drug due to the chance of harmful effects on the baby. Current research has not yet fully established safety for pediatric patients.<xref ref-type="bibr" rid="article-25891.r35">[35]</xref><xref ref-type="bibr" rid="article-25891.r30">[30]</xref></p>
          </list-item>
        </list>
        <p>
<bold>USFDA&#x000a0;Boxed Warning</bold>
</p>
        <p>Do not administer nimodipine by parenteral routes. Serious, life-threatening adverse events, including death, cardiac arrest, hypotension, cardiovascular collapse, and bradycardia, have been reported when the drug&#x000a0;is injected parenterally.&#x000a0;The IV formulation of nimodipine is currently available in Europe but is not FDA-approved, so it is not available in the U.S.<xref ref-type="bibr" rid="article-25891.r25">[25]</xref></p>
      </sec>
      <sec id="article-25891.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Blood pressure monitoring is necessary for patients&#x000a0;administered nimodipine as it can cause hypotension. The risk of hypotension is&#x000a0;elevated in the following scenarios:<xref ref-type="bibr" rid="article-25891.r36">[36]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>The plasma concentration of nimodipine&#x000a0;is elevated&#x000a0;by medications that moderately or weakly inhibit CYP3A4. Therefore, the patient's blood pressure&#x000a0;must be closely monitored if nimodipine is&#x000a0;administered concomitantly with&#x000a0;CYP3A4 inhibitors; reducing the nimodipine dose may be necessary.</p>
          </list-item>
          <list-item>
            <p>Nimodipine may&#x000a0;augment the blood pressure reduction&#x000a0;of concomitantly administered antihypertensives (eg, diuretics, &#x003b2;-blockers, ACE inhibitors, calcium antagonists, &#x003b1;-blockers, PDE5 inhibitors, &#x003b1;-methyldopa). Reducing the nimodipine dosage to prevent hypotension may be required.</p>
          </list-item>
          <list-item>
            <p>Patients with SAH should be monitored for hyponatremia, seizures, and vasospasm, especially during the 4 to 14-day "vasospasm window."<xref ref-type="bibr" rid="article-25891.r37">[37]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients prescribed nimodipine are at risk for&#x000a0;elevated intracranial pressure and rebleeding.<xref ref-type="bibr" rid="article-25891.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Patients with&#x000a0;SAH&#x000a0;must be monitored&#x000a0;with&#x000a0;comprehensive neurological examinations and grading scales (eg, Fisher grading scale).<xref ref-type="bibr" rid="article-25891.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Patients'&#x000a0;global disability and recovery should be monitored using the Glasgow Outcome Scale-Extended (GOSE).<xref ref-type="bibr" rid="article-25891.r40">[40]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25891.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Acute&#x000a0;toxicity due to overdose can cause significant hypotension, cardiac arrhythmia, nausea, and vomiting. Refractory, nimodipine-induced vasoplegia&#x000a0;may occur.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>No specific antidote is available. Overdoses are managed initially by discontinuing nimodipine and treating&#x000a0;symptoms. Gastric lavage&#x000a0;may be considered&#x000a0;if the toxicity is due to oral intake, and charcoal can&#x000a0;be administered in emergencies. Hypotension is managed with inotropes, and arrhythmias are managed by cardiologists and emergency department staff. Since nimodipine is highly protein-bound, dialysis is unlikely to be beneficial.<xref ref-type="bibr" rid="article-25891.r41">[41]</xref><xref ref-type="bibr" rid="article-25891.r42">[42]</xref><bold>&#x000a0;</bold>Recent case reports suggest hydroxocobalamin as a potential rescue therapy for nimodipine-induced refractory vasoplegia.<xref ref-type="bibr" rid="article-25891.r43">[43]</xref></p>
      </sec>
      <sec id="article-25891.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Management&#x000a0;of aneurysmal subarachnoid hemorrhage with nimodipine is best carried out by&#x000a0;an interprofessional healthcare team. A cardiologist or internal medicine specialist frequently initiates this treatment. Nurses administer and monitor nimodipine treatment in the intensive care unit (ICU) and the neurosurgical floor.&#x000a0;Neuro-intensivists and neurosurgeons play a crucial role in&#x000a0;managing complex SAH cases. Before initiating nimodipine therapy, a pharmacist should be consulted on dosing and drug interactions. Interprofessional coordination of effort permits the healthcare team to obtain optimal outcomes with minimal adverse events. One study has&#x000a0;demonstrated that early and aggressive care of SAH leads to a significant&#x000a0;improvement in survival and favorable outcomes.<xref ref-type="bibr" rid="article-25891.r44">[44]</xref></p>
        <p>When administering nimodipine,&#x000a0;providers must be aware&#x000a0;of&#x000a0;hypotension as an adverse effect. After administration, careful blood pressure monitoring is necessary, especially in patients concomitantly receiving CYP3A4 inhibitors and antihypertensives. Administration of nimodipine is possible by pushing the tablet contents through&#x000a0;a nasogastric tube. In these cases, oral nimodipine should be labeled&#x000a0;and kept separate to avoid its administration intravenously.&#x000a0;An interprofessional team approach and open communication between clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists are necessary to&#x000a0;optimize patient outcomes with&#x000a0;nimodipine&#x000a0;therapy.</p>
      </sec>
      <sec id="article-25891.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25891&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25891">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25891/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25891">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25891.s11">
        <title>References</title>
        <ref id="article-25891.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allen</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Preziosi</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Battye</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boone</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Boone</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chou</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Crabbe</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lavik</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Rosenbloom</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Dorsey</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Ingram</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Mellits</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Bertsch</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Boisvert</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Hundley</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Transou</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage.</article-title>
            <source>N Engl J Med</source>
            <year>1983</year>
            <month>Mar</month>
            <day>17</day>
            <volume>308</volume>
            <issue>11</issue>
            <fpage>619</fpage>
            <page-range>619-24</page-range>
            <pub-id pub-id-type="pmid">6338383</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effect of hyperbaric oxygen combined with nimodipine on treatment of diffuse brain injury.</article-title>
            <source>Exp Ther Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>15</volume>
            <issue>6</issue>
            <fpage>4651</fpage>
            <page-range>4651-4658</page-range>
            <pub-id pub-id-type="pmid">29805482</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wienke</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tatagiba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gharabaghi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramina</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Ganslandt</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zenk</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engelhorn</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Matthies</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Westermaier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Antoniadis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pedro</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>von Eckardstein</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kretschmer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kornhuber</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steighardt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barker</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Strauss</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic nimodipine treatment for cochlear and facial nerve preservation after vestibular schwannoma surgery: a randomized multicenter Phase III trial.</article-title>
            <source>J Neurosurg</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>124</volume>
            <issue>3</issue>
            <fpage>657</fpage>
            <page-range>657-64</page-range>
            <pub-id pub-id-type="pmid">26274985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frediani</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patruno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Valentini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bussone</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Is nimodipine useful in migraine prophylaxis? Further considerations.</article-title>
            <source>Headache</source>
            <year>1990</year>
            <month>May</month>
            <volume>30</volume>
            <issue>6</issue>
            <fpage>363</fpage>
            <page-range>363-5</page-range>
            <pub-id pub-id-type="pmid">2196239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sin</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Shafeeq</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>ZD</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine for the treatment of otolaryngic indications.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2018</year>
            <month>Sep</month>
            <day>15</day>
            <volume>75</volume>
            <issue>18</issue>
            <fpage>1369</fpage>
            <page-range>1369-1377</page-range>
            <pub-id pub-id-type="pmid">30190294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Huo</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>QJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of nimodipine on postoperative delirium in elderly under general anesthesia: A prospective, randomized, controlled clinical trial.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2017</year>
            <month>May</month>
            <volume>96</volume>
            <issue>19</issue>
            <fpage>e6849</fpage>
            <pub-id pub-id-type="pmid">28489775</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pelliccia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sciaretta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matricardi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine treatment for drug-resistant childhood epilepsy.</article-title>
            <source>Dev Med Child Neurol</source>
            <year>1990</year>
            <month>Dec</month>
            <volume>32</volume>
            <issue>12</issue>
            <fpage>1114</fpage>
            <pub-id pub-id-type="pmid">2126773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Orgasmic headache treated with nimodipine.</article-title>
            <source>J Sex Med</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>311</fpage>
            <pub-id pub-id-type="pmid">24112519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumpinsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nahas</surname>
                <given-names>SJ</given-names>
              </name>
            </person-group>
            <article-title>Bath-Related Headache.</article-title>
            <source>Curr Pain Headache Rep</source>
            <year>2018</year>
            <month>Aug</month>
            <day>02</day>
            <volume>22</volume>
            <issue>10</issue>
            <fpage>68</fpage>
            <pub-id pub-id-type="pmid">30073574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maria</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Abd-Elgawad</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Soliman</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>El-Dahan</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Jablonski</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine Ophthalmic Formulations for Management of Glaucoma.</article-title>
            <source>Pharm Res</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>809</fpage>
            <page-range>809-824</page-range>
            <pub-id pub-id-type="pmid">28155073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pugazenthi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Lauzier</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Lele</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Huguenard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dhar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Zipfel</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Athiraman</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Conditioning-based therapeutics for aneurysmal subarachnoid hemorrhage - A critical review.</article-title>
            <source>J Cereb Blood Flow Metab</source>
            <year>2024</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>3</issue>
            <fpage>317</fpage>
            <page-range>317-332</page-range>
            <pub-id pub-id-type="pmid">38017387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bellapart</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Laupland</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Malacova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Paratz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine prophylaxis in aneurysmal subarachnoid hemorrhage, a question of tradition or evidence: A scoping review.</article-title>
            <source>J Clin Neurosci</source>
            <year>2024</year>
            <month>May</month>
            <volume>123</volume>
            <fpage>91</fpage>
            <page-range>91-99</page-range>
            <pub-id pub-id-type="pmid">38564967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ditz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Matone</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Schwachenwald</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>K&#x000fc;chler</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Risks of nimodipine dose reduction during the high-risk period for delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.</article-title>
            <source>Neurosurg Rev</source>
            <year>2024</year>
            <month>Jan</month>
            <day>09</day>
            <volume>47</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <pub-id pub-id-type="pmid">38191859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pickard</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Illingworth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Teasdale</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Foy</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Humphrey</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Richards</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.</article-title>
            <source>BMJ</source>
            <year>1989</year>
            <month>Mar</month>
            <day>11</day>
            <volume>298</volume>
            <issue>6674</issue>
            <fpage>636</fpage>
            <page-range>636-42</page-range>
            <pub-id pub-id-type="pmid">2496789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teasdale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gullan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heiskanan</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>PV</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mendelow</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The effect of nimodipine on outcome after head injury: a prospective randomised control trial. The British/Finnish Co-operative Head Injury Trial Group.</article-title>
            <source>Acta Neurochir Suppl (Wien)</source>
            <year>1990</year>
            <volume>51</volume>
            <fpage>315</fpage>
            <page-range>315-6</page-range>
            <pub-id pub-id-type="pmid">2089926</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaste</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fogelholm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eril&#x000e4;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Palom&#x000e4;ki</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Murros</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rissanen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sarna</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke.</article-title>
            <source>Stroke</source>
            <year>1994</year>
            <month>Jul</month>
            <volume>25</volume>
            <issue>7</issue>
            <fpage>1348</fpage>
            <page-range>1348-53</page-range>
            <pub-id pub-id-type="pmid">8023348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Teasdale</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine in traumatic subarachnoid haemorrhage: a re-analysis of the HIT I and HIT II trials.</article-title>
            <source>Acta Neurochir (Wien)</source>
            <year>1996</year>
            <volume>138</volume>
            <issue>10</issue>
            <fpage>1163</fpage>
            <page-range>1163-7</page-range>
            <pub-id pub-id-type="pmid">8955434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <article-title>European multicenter trial of nimodipine in the prophylaxis of classic migraine (migraine with aura). Migraine-Nimodipine European Study Group (MINES).</article-title>
            <source>Headache</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>29</volume>
            <issue>10</issue>
            <fpage>639</fpage>
            <page-range>639-42</page-range>
            <pub-id pub-id-type="pmid">2693406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nag</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Varma</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A randomized double-blind controlled study of nimodipine in acute cerebral ischemic stroke.</article-title>
            <source>Indian J Physiol Pharmacol</source>
            <year>1998</year>
            <month>Oct</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>555</fpage>
            <page-range>555-8</page-range>
            <pub-id pub-id-type="pmid">10874361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pantoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Inzitari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beneke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erkinjuntti</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wallin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial.</article-title>
            <source>J Neurol Sci</source>
            <year>2000</year>
            <month>Apr</month>
            <day>15</day>
            <volume>175</volume>
            <issue>2</issue>
            <fpage>124</fpage>
            <page-range>124-34</page-range>
            <pub-id pub-id-type="pmid">10831773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Haan</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Vermeulen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Limburg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Very Early Nimodipine Use in Stroke (VENUS): a randomized, double-blind, placebo-controlled trial.</article-title>
            <source>Stroke</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>461</fpage>
            <page-range>461-5</page-range>
            <pub-id pub-id-type="pmid">11157183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kronvall</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Undr&#x000e9;n</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Romner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>S&#x000e4;veland</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cronqvist</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>OG</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.</article-title>
            <source>J Neurosurg</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>110</volume>
            <issue>1</issue>
            <fpage>58</fpage>
            <page-range>58-63</page-range>
            <pub-id pub-id-type="pmid">18847340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aldrich</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Diringer</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Schmutzhard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faleck</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saville</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Proskin</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>RL</given-names>
              </name>
              <collab>NEWTON Investigators</collab>
            </person-group>
            <article-title>Single-Dose Intraventricular Nimodipine Microparticles Versus Oral Nimodipine for Aneurysmal Subarachnoid Hemorrhage.</article-title>
            <source>Stroke</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>1142</fpage>
            <page-range>1142-1149</page-range>
            <pub-id pub-id-type="pmid">32138631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aldrich</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Diringer</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Schmutzhard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Faleck</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saville</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>RL</given-names>
              </name>
              <collab>NEWTON Investigators</collab>
            </person-group>
            <article-title>Clinical Trial Protocol: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults with Aneurysmal Subarachnoid Hemorrhage [NEWTON-2 (Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After SubarachNoid Hemorrhage)].</article-title>
            <source>Neurocrit Care</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-97</page-range>
            <pub-id pub-id-type="pmid">30014184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carlson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Macdonald</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Shuttleworth</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine Reappraised: An Old Drug With a Future.</article-title>
            <source>Curr Neuropharmacol</source>
            <year>2020</year>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-82</page-range>
            <pub-id pub-id-type="pmid">31560289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitfield</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Pickard</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine.</article-title>
            <source>Br J Hosp Med</source>
            <string-date>1994 Nov 16-Dec 13</string-date>
            <volume>52</volume>
            <issue>10</issue>
            <fpage>539</fpage>
            <page-range>539-40</page-range>
            <pub-id pub-id-type="pmid">7858806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahmoud</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Isse</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine Pharmacokinetic Variability in Various Patient Populations.</article-title>
            <source>Drugs R D</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>4</issue>
            <fpage>307</fpage>
            <page-range>307-318</page-range>
            <pub-id pub-id-type="pmid">32902829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diringer</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Claude Hemphill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Shutter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vespa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bruder</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Citerio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gress</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hoh</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Lanzino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Le Roux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schmutzhard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stocchetti</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Treggiari</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Vergouwen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zipfel</surname>
                <given-names>G</given-names>
              </name>
              <collab>Neurocritical Care Society</collab>
            </person-group>
            <article-title>Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference.</article-title>
            <source>Neurocrit Care</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>211</fpage>
            <page-range>211-40</page-range>
            <pub-id pub-id-type="pmid">21773873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Macdonald</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>H&#x000e4;nggi</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>NU</given-names>
              </name>
              <name>
                <surname>Darsaut</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Carlson</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Etminan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Aldrich</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Diringer</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bleck</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Suarez</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>NEWTON-2 Cisternal (Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage): A Phase 2, Multicenter, Randomized, Open-Label Safety Study of Intracisternal EG-1962 in Aneurysmal Subarachnoid Hemorrhage.</article-title>
            <source>Neurosurgery</source>
            <year>2020</year>
            <month>Dec</month>
            <day>15</day>
            <volume>88</volume>
            <issue>1</issue>
            <fpage>E13</fpage>
            <page-range>E13-E26</page-range>
            <pub-id pub-id-type="pmid">32985652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r30">
          <label>30</label>
          <element-citation publication-type="book">
            <chapter-title>Nimodipine</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>1</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heffren</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McIntosh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Reiter</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine for the prevention of cerebral vasospasm after subarachnoid hemorrhage in 12 children.</article-title>
            <source>Pediatr Neurol</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>52</volume>
            <issue>3</issue>
            <fpage>356</fpage>
            <page-range>356-60</page-range>
            <pub-id pub-id-type="pmid">25585913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Turnbull</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Freeman</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine-induced junctional bradycardia in an elderly patient with subarachnoid hemorrhage.</article-title>
            <source>Pharmacogenomics</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>387</fpage>
            <page-range>387-392</page-range>
            <pub-id pub-id-type="pmid">32284009</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>De Jesus</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>S&#x000e1;nchez Jim&#x000e9;nez</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vicenty</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Potential Association Between Acute Colonic Pseudo-Obstruction (Ogilvie Syndrome) and Oral Nimodipine: Report of Two Cases.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Aug</month>
            <volume>14</volume>
            <issue>8</issue>
            <fpage>e28039</fpage>
            <pub-id pub-id-type="pmid">36120238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000fc;ck</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ahr</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuhlmann</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Nimodipine. Potential for drug-drug interactions in the elderly.</article-title>
            <source>Drugs Aging</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-42</page-range>
            <pub-id pub-id-type="pmid">7620235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>133</volume>
            <issue>2</issue>
            <fpage>e174</fpage>
            <page-range>e174-e180</page-range>
            <pub-id pub-id-type="pmid">30575639</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hajizadeh Barfejani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rabinstein</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wijdicks</surname>
                <given-names>EFM</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>SL</given-names>
              </name>
            </person-group>
            <article-title>Poor Utilization of Nimodipine in Aneurysmal Subarachnoid Hemorrhage.</article-title>
            <source>J Stroke Cerebrovasc Dis</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>2155</fpage>
            <page-range>2155-2158</page-range>
            <pub-id pub-id-type="pmid">31103551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muehlschlegel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Subarachnoid Hemorrhage.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>1623</fpage>
            <page-range>1623-1657</page-range>
            <pub-id pub-id-type="pmid">30516599</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heuer</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Elliott</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Winn</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>LeRoux</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Relationship between intracranial pressure and other clinical variables in patients with aneurysmal subarachnoid hemorrhage.</article-title>
            <source>J Neurosurg</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>408</fpage>
            <page-range>408-16</page-range>
            <pub-id pub-id-type="pmid">15352597</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frontera</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Claassen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wartenberg</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Temes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Connolly</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale.</article-title>
            <source>Neurosurgery</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-7; discussion 21-7</page-range>
            <pub-id pub-id-type="pmid">16823296</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Boase</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Temkin</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Giacino</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Markowitz</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Maas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Teasdale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manley</surname>
                <given-names>GT</given-names>
              </name>
            </person-group>
            <article-title>A Manual for the Glasgow Outcome Scale-Extended Interview.</article-title>
            <source>J Neurotrauma</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>38</volume>
            <issue>17</issue>
            <fpage>2435</fpage>
            <page-range>2435-2446</page-range>
            <pub-id pub-id-type="pmid">33740873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>St-Onge</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dub&#x000e9;</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Gosselin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Guimont</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Godwin</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Archambault</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Chauny</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Frenette</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Darveau</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Le Sage</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Poitras</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Provencher</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Juurlink</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Blais</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Treatment for calcium channel blocker poisoning: a systematic review.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>926</fpage>
            <page-range>926-44</page-range>
            <pub-id pub-id-type="pmid">25283255</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elikowski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ma&#x00142;ek-Elikowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Piestrzeniewicz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ferta&#x00142;a</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zawodna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ganowicz-Kaatz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baszko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sm&#x000f3;l</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Takotsubo syndrome after nimodipine-induced hypotension treated with norepinephrine in a female with subarachnoid hemorrhage.</article-title>
            <source>Pol Merkur Lekarski</source>
            <year>2020</year>
            <month>Aug</month>
            <day>22</day>
            <volume>49</volume>
            <issue>286</issue>
            <fpage>236</fpage>
            <page-range>236-240</page-range>
            <pub-id pub-id-type="pmid">32827417</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clifford</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Madhok</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Mohindra</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Rescue of Nimodipine-Induced Refractory Vasoplegia With Hydroxocobalamin in Subarachnoid Hemorrhage: A Case Report.</article-title>
            <source>Crit Care Explor</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>2</volume>
            <issue>10</issue>
            <fpage>e0205</fpage>
            <pub-id pub-id-type="pmid">33063021</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25891.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Mufti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bassily</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Holstein</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Ani</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matluck</surname>
                <given-names>NE</given-names>
              </name>
              <name>
                <surname>Kamal</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nuoman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>S Ali</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Al-Shammari</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>El-Ghanem</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gandhi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Amuluru</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Neurocritical care management of poor-grade subarachnoid hemorrhage: Unjustified nihilism to reasonable optimism.</article-title>
            <source>Neuroradiol J</source>
            <year>2021</year>
            <month>Dec</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-551</page-range>
            <pub-id pub-id-type="pmid">34476991</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
